Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma (MM)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2012 by Shandong Lanjin Pharmaceuticals Co.,Ltd.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Shandong Lanjin Pharmaceuticals Co.,Ltd Identifier:
First received: April 4, 2012
Last updated: August 1, 2012
Last verified: April 2012
The purpose of the study is to evaluate the safety and effectiveness of melphalan for injection for autologous stem cell transplant in multiple myeloma

Condition Intervention
Multiple Myeloma
Drug: Melphalan

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Single Arm, Open Label Study of Autologous Stem Cell Transplantation With High Dose Melphalan in Patients With Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by Shandong Lanjin Pharmaceuticals Co.,Ltd:

Primary Outcome Measures:
  • 1 year Progression Free Survival [ Time Frame: 20 months ] [ Designated as safety issue: No ]
    Plan to enroll all trial subjects within 8 months and follow up 1 year for each subject after enrollment

Estimated Enrollment: 60
Study Start Date: November 2011
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: autologous stem cell transplant Drug: Melphalan
powder for injection, 200mg/m2, uses after reconstituted within 24 hours


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with greater or equal to 18 years, with a upper age limit of 65 years are eligible.
  • Multiple myeloma patients, symptoms conform to diagnosis of multiple myeloma of IMWG2003/WHO2008 criteria.
  • Patients with responsive disease after induction therapy not more than 6 courses of treatment
  • A complete response
  • A very good partial response
  • A partial response
  • At least 4 weeks long from last cytotoxic treatment(exclude Bortezomib, thalidomide, dexamethasone);
  • Eastern Cooperative Oncology Group (ECOG) scored 0 or 1 Patient has an absolute neutrophil count of ≥1.5×109/L and platelet count≥80×109/L;
  • Calculated creatinine clearance >50ml/min by Cockcroft-Gault formula or collect urine within 24 hours.
  • Patient with a total bilirubin ≤1.5 times of normal upper limit, AST,ALT≤2.5times of normal upper limit;
  • Cardio-pulmonary function is adequate to conduct autologous stem cell transplant.
  • Ratio of body weight and ideal body weight <175%;
  • All patients should have a life expectancy of more than 12 weeks
  • Signed informed consent form voluntarily

Exclusion Criteria:

  • CD34 positive hematopoietic stem cell collected <2.0×106/kg
  • Patients have a psychiatric history
  • Female subject is pregnant or breast-feeding
  • Patients are hypersensitive to this trial product or other alkylating agents
  • Participate of other clinical trials within the past 4 weeks Active CNS lesions
  • Concomitant of active infection or positive of HIV antibody
  • Concomitant of other un-healed malignancy
  • Left ventricular ejection fraction≤50%
  • Patients with serious thrombosis
  • Any severe concomitant disease that will expose study subjects to unacceptable risks.
  • Patients not suitable to enroll by investigators considerations.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01572688

Hematologic Hospital of Chinese Academy of Medical Sciences Recruiting
Tianjin, China
Contact: Lu G Qiu    +86-022-23909172      
Contact: Jian J Yu, Master    +8615336402751   
Sponsors and Collaborators
Shandong Lanjin Pharmaceuticals Co.,Ltd
Principal Investigator: Lugui Qiu, master Chinese Academy of Medical Sciences
  More Information

Responsible Party: Shandong Lanjin Pharmaceuticals Co.,Ltd Identifier: NCT01572688     History of Changes
Other Study ID Numbers: RG0276 
Study First Received: April 4, 2012
Last Updated: August 1, 2012
Health Authority: China: Food and Drug Administration

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Vascular Diseases
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Physiological Effects of Drugs processed this record on May 23, 2016